Login to Your Account

U.S. patent disclosures

Friday, December 27, 2013
Immunomedics Inc., of Morris Plains, N.J., received U.S. Patent No. 8,574,575 for RS7 antibodies. The patent relates to methods of use of the company’s TROP-2 antibody, and the allowed claim covers the use of IMMU-132, a SN-38 conjugate of TROP-2, for the treatment of cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription